| 房颤危险分层及抗凝治疗研究进展 |
| |
| 引用本文： | 王静.房颤危险分层及抗凝治疗研究进展[J].世界临床药物,2012(6):330-335. |
| |
| 作者姓名： | 王静 |
| |
| 作者单位： | 天津市第三医院心内科 |
| |
| 摘 要： | 房颤(AF)是临床常见的心律失常,脑卒中是其主要并发症。临床治疗的重要环节是栓塞预防,而AF患者的栓塞危险分层有助于临床个体化治疗。本文分析权威指南的AF栓塞危险分层标准,综述达比加群酯、利伐沙班和阿哌沙班等新型抗凝药的临床应用研究进展。
|
| 关 键 词： | 房颤 抗凝治疗 达比加群 利伐沙班 阿哌沙班 |
Risk stratification of atrial fibrillation and the research progress on anticoagulant therapy |
| |
| WANG Jing.Risk stratification of atrial fibrillation and the research progress on anticoagulant therapy[J].WORLD CLINICAL DRUGS,2012(6):330-335. |
| |
| Authors: | WANG Jing |
| |
| Institution: | WANG Jing(Department of Cardiology,Tianjin Third Hospital,Tianjin 300250,China) |
| |
| Abstract: | Atrial fibrillation(AF) is a kind of common arrhythmia in clinic.Stroke is its main complication.Prevention from embolism is an important treatment of AF.The risk stratification of AF patients can benefit to the clinical individual treatment.This paper analyzes the AF embolism risk stratification criteria in guideline,and reviews the application progress of new anticoagulant drugs,such as dabigatran ester,rivaroxaban and apixaban. |
| |
| Keywords: | atrial fibrillation anticoagulation dabigatran rivaroxaban apixaban |
| 本文献已被 CNKI 等数据库收录！ |
